Skip to main content

Table 2 Administration of corticosteroids, stratified by outcome

From: Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis

  All (n = 226) Non-survivors (n = 135) Survivors (n = 91) p value
Corticosteroid prescribed
 Methylprednisolone 213 (94.2) 132 (62.0) 83 (38.0) 0.0004
 Prednisolone 41 (18.1) 11 (73.2) 30 (26.8) 0.0007
 Dexamethasone 5 (2.2) 4 (80.0) 1 (20.0) 0.4470
Maximum dose (methylprednisolone equivalent, mg) 80.0 (40.0–80.0) 80.0 (40.0–80.0) 80.0 (40.0–80.0) 0.0821
Days of corticosteroid treatment 7.0 (4.0–12.0) 6.0 (3.0–11.0) 9.0 (5.0–12.0) 0.0069
Days of maximum dose 3.0 (2.0–5.0) 3.0 (1.0–5.0) 4.0 (2.0–5.0) 0.0287
Days from symptom onset to corticosteroid treatment 13.0 (10.0–16.0) 14.0 (11.0–18.0) 11.0 (9.0–14.0) 0.0031
Days from hospital admission to corticosteroid treatment 1.0 (0.0–3.0) 1.0 (0.0–4.0) 1.0 (0.0–2.0) 0.1892
Days from ARDS to corticosteroid treatment 0.0 (0.0–2.0) 1.0 (0.0–2.0) 0.0 (− 1.0 to 1.0) 0.0102
Days from ventilation to corticosteroid treatment − 1.0 (− 3.0 to 0.0) − 1.0 (− 3.0 to 0.0) − 2.0 (− 4.0 to 1.0) 0.7576
  1. Data are n (%) or medium (IQR). For continuous variables, t test or Mann–Whitney U test was used to calculate the p value unless otherwise noted. For categorical variables, chi-square test was used to calculate the p value unless otherwise noted